About Encala

Encala is a structured lipid matrix formulated of lysophosphatidylcholine monoglycerides and essential fatty acids and was developed specifically for patients with cystic fibrosis (CF)

A non-GMO, taste-neutral, gluten-free, plant-based powder designed to be mixed into meals, beverages, or snacks

Clinically proven to increase overall fat absorption, weight, and height

Supplies essential fatty acids and choline

A source of 100 healthy calories per serving


Multi-Serving Pouch

Ingredients: Tapioca Maltodextrin, Monoglycerides, Soybean Lecithin, Oleic Acid and Linolenic Acid, Calcium Chloride, Water.

Contains: Soy.

Encala works in two ways:

Encala can help patients with CF who have exocrine pancreatic insufficiency (EPI)

Pancreatic enzyme replacement therapy (PERT) is a vital aspect of treatment for patients with CF because it supplies essential digestive enzymes. However, even with recommended doses of PERT, fat malabsorption often persists. Some of the ingested fat isn’t broken down and absorbed through the mucosa of the small intestine.

Despite PERT, the following issues may persist:

Pancreatic enzyme replacement therapy (PERT) is a vital aspect of treatment for patients with PI because it supplies essential digestive enzymes. However, even with recommended doses of PERT, fat malabsorption often persists. Some of the fat broken down by PERT is not readily absorbed through the mucosa of the small intestine.

Pancreatic lipase is not required for the digestion and absorption of the fat calories contained in Encala.1 
Encala is readily absorbed through the mucosa of the small intestine and enhances the absorption of fats from the associated meal. This two-pronged approach to improving caloric absorption helps patients achieve their weight, height, and BMI goals in a healthier, easier way.

Adequate nutrition and growth depend on optimizing ingestion, digestion, and absorption

CF has a major impact on all three:

The number of calories consumed—food ingestion—needs to be increased to compensate for malabsorption of calories through the small intestine.

Digestion of key nutrients, especially fat and fat-soluble vitamins, is impaired by CF-related PI because the pancreas does not produce and secrete enough of the fat-digesting enzyme, lipase. As a result, fat cannot be fully broken down and absorbed through the intestinal wall.

Normal coefficient of fat absorption (CFA) is >93%, but in patients with CF on PERT, these levels can range from 70% to 85%.2-5 In fact, in one study, 24% of patients on PERT had CFA <85%, which was associated with significantly lower Z scores for weight.6

Encala improves all three.

Scroll to Top